Clinical Trial Update: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating autologous CD34+ hematopoietic stem cells gene-corrected from HbS to HbA to treat severe sickle cell disease; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HbS-to-HbA gene-corrected autologous CD34+ hematopoietic stem cells

Snippet

Sponsor: Kamau Therapeutics | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: RECRUITING